Figure 3. Multivariable Cox’s regression analysis of BMI and other clinical variables associated with response to ICI in EC patients.

Forest plots of adjusted HRs and 95% CIs for patients with normal BMI (BMI 18.5–24.9 kg/m²) (reference group) compared with overweight (BMI 25–29.9 kg/m²) and obese (BMI > 30 kg/m²) for (A) PFS and (B) OS (n = 524) Analysis was adjusted for age, self-reported race, histology, checkpoint inhibitor treatment, combination therapies, baseline performance status, stage at diagnosis, prior lines of therapy, and previous pelvic radiotherapy. Endo-LG, endometrial low grade; Endo-HG, endometrial high grade; Un-/dediff, un/dedifferentiated; Len/pem, lenvatinib/pembrolizumab; Treme/durva, tremelimumab/durvalumab.